Ultra Nasdaq Biotechnology 2X ETF BIB

$59.46 +0.84 (1.43%)

Valuation

Market cap
—
Revenue TTM
—
Net income TTM
—
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
4,567
Avg volume
—
Day's range
$58.70 – $59.72
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Latest news

Stocktwits

jjon2121 Oct 21, 11:44 PM
$LABD $LABU $XBI $IBB $BIB This buyout hasn't hit the main sites yet. EQT/QIAGEN 10.8B. Don't know what effect it will have & when. https://www.google.com/search?q=Qiagen+(QGEN&sourceid=chrome&ie=UTF-8
2 replies
macrossluvsrobotech Oct 21, 4:58 PM
$LXRX + $NVO - $LLY = 😁😉💪😎 $BIB Time for an oral pill, lower capex, lower probability of contamination with liquid injectables vs a room temp shelf stable oral pill, like LX9851 from $LXRX and that $NVO committed a Billion dollars for. Just on $NVO deal puts $LXRX at 2.25 a share. 1Bil divided by $LXRX shares 445mil is 2.25 a share, cash on hand: 190.61 Mil ( with 51.4 long term debt subtracted= 139.2mil ) = 31 cents: 2.25+.31 cents = 2.56 a share. And 2.68 if we consider the full gross cash they have on hand: 190.61 Mil. GLP-1 injections recalled nationwide over sterility concerns The recall affects 23 vials of prescription injections and follows an earlier FDA warning about the company's sterile drug production practices. https://www.foxbusiness.com/healthcare/glp-1-injections-recalled-nationwide-over-sterility-concerns Novo Nordisk + $LXRX = https://www.fiercebiotech.com/biotech/novo-inks-1b-lexicon-obesity-deal-after-seeing-preclinical-prospect-shine-semaglutide Not counting the pending submittal catalyst for the FIRST ever Oral Pill for Type 1 Diabetes, to control sugar, and lower the need to constantly do painful injections of insulin.
0 replies
macrossluvsrobotech Oct 21, 3:05 PM
$LXRX Big News! Two Breakthrough Papers Drop Ahead of Boston Heart Summit 🫀📄🔥 Today, top medical journals proved Lexicon's drug sotagliflozin beats the competition where it matters most: 1. Clot-Stopping (JCI): Science believed clot-forming blood cells (platelets) had no "SGLT" doors. Researchers just proved they do, and sota shuts them to stop heart attacks and strokes! Tested head-to-head, sota calmed platelets while competitor empagliflozin ($LLY / Jardiance) completely failed! Best of all, sota stops dangerous clots with zero bleeding risk. 2. Healing Stiff Hearts (JMCC Plus): Sota reverses heart thickening, clears stiff scars, and recharges starving heart cells with energy in HCM. The Roadshow: Lexicon put top expert Dr. Sharlene Day (Penn Medicine) on the Boston HCM Summit stage tomorrow to show it works without weakening the heart like $13.1B Camzyos. With Phase 3 SONATA-HCM fully enrolled, LXRX is priced at $0 inside a ~$770M EV. This is a massive disconnect. $NVO $BIB
0 replies
macrossluvsrobotech Oct 21, 2:42 PM
$LXRX $LXRX Drops Peer-Reviewed Proof Ahead of Boston Summit 🫀📄🔥 Lexicon announced 2 major peer-reviewed publications validating sotagliflozin’s dual SGLT1/2 dominance: 1. JCI Breakthrough (Novel Science): Proves SGLT1 is functional on platelets! Sota attenuates platelet activation & thrombosis WITHOUT bleeding risk—unlike Jardiance (empagliflozin), which failed completely. This explains why sota slashed stroke/MI in SCORED! 2. JMCC Plus (HCM Paper): Proves sota normalizes diastolic function, reverses fibrosis, and upregulates mitochondrial energy in HCM. This isn't redressed PR; it’s apex validation in JCI & JMCC Plus, weaponizing KOL Dr. Sharlene Day (Penn Medicine) 24 hrs before taking the podium at the International HCM Summit in Boston (Oct 22–25). From HCMA grassroots to Boston KOLs backed by fresh JCI data, roadshow confidence is palpable. BMS paid $13.1B for MyoKardia in HCM. At ~$770M EV, LXRX’s HCM pipeline is priced at $0.00. NFA. $NVO $BIB $VTRS $LLY
0 replies
jjon2121 Oct 13, 3:58 PM
$LABD $LABD $LABU $XBI $IBB $BIB @SOUNDSAWESOME @AUTANA @FRYEGUY121 New buyout announcement Steris/Xodus 2.1B https://www.medtechdive.com/news/steris-inks-21b-xodus-buyout-to-expand-consumables-portfolio/832822/
1 replies
macrossluvsrobotech Oct 9, 3:23 AM
$LXRX Biopharma M&A Surge: Viatris Buys Pacira — And Mike Exton Is Watching 👀💰 Viatris ($VTRS) just agreed to acquire Pacira ($PCRX) for $36.50/sh in all cash ($1.65B equity value)—a massive 44.8% premium over Wednesday's $25.20 close. The target? Pacira’s non-opioid, opioid-sparing pain franchise. And guess who just publicly liked the announcement on LinkedIn? 👉 Lexicon CEO Dr. Mike Exton. How this connects directly to $LXRX & $NVO: 1. Non-Opioid Scarcity: Big Pharma pays billions for opioid-sparing assets. Lexicon holds LX9211 (first-in-class AAK1 non-opioid neuropathic pain). 2. The Buyout Arbitrage: At ~$1.70 / ~$770M EV, LXRX is deeply mispriced. Novo Nordisk already committed $1.0B in milestones/royalties for ACSL5. Under Novo’s CMD Slide 13 bolt-on playbook, buying LXRX outright extinguishes ~$925M in milestones while securing 100% of LX9851 & LX9211. When CEOs track peer M&A premiums, smart money prepares for the tender offer. NFA. $NVO $BIB
0 replies
macrossluvsrobotech Oct 8, 4:54 PM
$LXRX Fox News Nails GLP-1 Toxicity: The ACSL5 Solution 🔬💅 Fox News broke the EADV 2026 study: 66% of GLP-1 users report nail disorders, with 39% suffering onycholysis (nails detaching) vs 9% of controls (4x+ risk)! When mass media warns that weight loss causes nails to fall off and hair loss (26% vs 12%), real-world GLP-1 abandonment (>50%) will surge. First principles show why Lexicon’s ACSL5 (LX9851) is the cure: 1. Gut-Local: Acts inside enterocytes—no systemic flooding starving nail matrices or hair follicles. 2. Natural Ileal Brake: Triggers endogenous, meal-timed GLP-1/PYY pulses instead of 24/7 artificial receptor overload. 3. Novo Slide 10 Synergy: -33% combo weight loss lets Novo slash peptide doses in half, eliminating peripheral toxicities while beating monotherapy. This is why Novo committed $1.0B to oral ACSL5. Fox: https://www.foxnews.com/health/people-weight-loss-drugs-report-fingernails-falling-researchers-uncover-surprising-link $NVO $LLY $VTRS $BIB
1 replies
macrossluvsrobotech Oct 7, 3:37 PM
$LXRX ExtonBurner’s Desperate Self-Own & Meme Auditing 🤡📉 Imagine spending your weekend peer-reviewing satirical background text in a meme illustration because you can't dispute the hard data: 1. Self-Own on Timeline: You literally admitted Class 2 resubmissions have a 6-month review clock! That’s the entire bull point: a Q4 filing puts the FDA decision in mid-2027—overlapping with Q1 '27 Phase 3 HCM data & H1 '27 Novo ACSL5 data. You just verified our catalyst schedule! 2. Fabricated Strawman: Nobody claims Sota "eliminates insulin." T1Ds lack beta cells. Sota is an oral ADJUNCT that reduces daily painful insulin injection burden, increases Time-in-Range, and cuts A1c. Historical first ever oral pill. 3. Guilt by Association: Screenshotting random retail posts to debate institutional milestone models is pure deflection. Institutional models track the H2 '26 $10M milestone & Novo Slide 13 bolt-on value. Fact-checking meme art won't save a short thesis. 🪦⚰️☠️💀 $NVO $VTRS $BIB $LLY
0 replies